Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free ZIVO Stock Alerts

ZIVO Bioscience (ZIVO) Competitors

ZIVO Bioscience logo
$3.69 0.00 (0.00%)
As of 05/14/2026 03:25 PM Eastern
Compare

ZIVO vs. HYFT, LIXT, KALA, IBIO, and SCLX

Should you buy ZIVO Bioscience stock or one of its competitors? MarketBeat compares ZIVO Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ZIVO Bioscience include MindWalk (HYFT), Lixte Biotechnology (LIXT), KALA BIO (KALA), iBio (IBIO), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry.

How does ZIVO Bioscience compare to MindWalk?

ZIVO Bioscience (NASDAQ:ZIVO) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

ZIVO Bioscience has higher earnings, but lower revenue than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIVO Bioscience$15.85K931.70-$7.78M-$2.59N/A
MindWalk$28.08M1.99-$21.69M-$0.20N/A

MindWalk has a consensus target price of $5.00, indicating a potential upside of 312.20%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than ZIVO Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
MindWalk
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

In the previous week, MindWalk had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for MindWalk and 1 mentions for ZIVO Bioscience. MindWalk's average media sentiment score of 0.93 beat ZIVO Bioscience's score of 0.00 indicating that MindWalk is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ZIVO Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
MindWalk
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ZIVO Bioscience has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

ZIVO Bioscience has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. ZIVO Bioscience's return on equity of 0.00% beat MindWalk's return on equity.

Company Net Margins Return on Equity Return on Assets
ZIVO BioscienceN/A N/A -2,240.92%
MindWalk -66.79%-69.37%-39.74%

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

MindWalk beats ZIVO Bioscience on 10 of the 17 factors compared between the two stocks.

How does ZIVO Bioscience compare to Lixte Biotechnology?

Lixte Biotechnology (NASDAQ:LIXT) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Lixte Biotechnology has higher earnings, but lower revenue than ZIVO Bioscience. Lixte Biotechnology is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lixte BiotechnologyN/AN/A-$6.01M-$1.24N/A
ZIVO Bioscience$15.85K931.70-$7.78M-$2.59N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lixte Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Lixte Biotechnology had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Lixte Biotechnology and 1 mentions for ZIVO Bioscience. Lixte Biotechnology's average media sentiment score of 0.99 beat ZIVO Bioscience's score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lixte Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ZIVO Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lixte Biotechnology has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

ZIVO Bioscience's return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Lixte BiotechnologyN/A -242.85% -115.18%
ZIVO Bioscience N/A N/A -2,240.92%

5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 9.5% of Lixte Biotechnology shares are held by company insiders. Comparatively, 21.5% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Lixte Biotechnology beats ZIVO Bioscience on 7 of the 12 factors compared between the two stocks.

How does ZIVO Bioscience compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

ZIVO Bioscience's return on equity of 0.00% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
KALA BION/A -12,971.16% -90.83%
ZIVO Bioscience N/A N/A -2,240.92%

ZIVO Bioscience has higher revenue and earnings than KALA BIO. ZIVO Bioscience is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KALA BION/AN/A-$26.98M-$166.50N/A
ZIVO Bioscience$15.85K931.70-$7.78M-$2.59N/A

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 2.2% of KALA BIO shares are held by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

KALA BIO presently has a consensus target price of $1,018.75, indicating a potential upside of 33,257.89%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts clearly believe KALA BIO is more favorable than ZIVO Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, KALA BIO had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for KALA BIO and 1 mentions for ZIVO Bioscience. KALA BIO's average media sentiment score of 0.28 beat ZIVO Bioscience's score of 0.00 indicating that KALA BIO is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
KALA BIO
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
ZIVO Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

KALA BIO has a beta of -2.23, suggesting that its share price is 323% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

Summary

KALA BIO beats ZIVO Bioscience on 8 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to iBio?

iBio (NASDAQ:IBIO) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

ZIVO Bioscience's return on equity of 0.00% beat iBio's return on equity.

Company Net Margins Return on Equity Return on Assets
iBioN/A -53.86% -46.48%
ZIVO Bioscience N/A N/A -2,240.92%

ZIVO Bioscience has lower revenue, but higher earnings than iBio. iBio is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iBio$400K133.27-$18.38M-$0.58N/A
ZIVO Bioscience$15.85K931.70-$7.78M-$2.59N/A

7.9% of iBio shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 2.8% of iBio shares are held by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

iBio presently has a consensus target price of $4.75, indicating a potential upside of 222.03%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than ZIVO Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iBio
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
3 Strong Buy rating(s)
3.17
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, iBio had 7 more articles in the media than ZIVO Bioscience. MarketBeat recorded 8 mentions for iBio and 1 mentions for ZIVO Bioscience. iBio's average media sentiment score of 0.15 beat ZIVO Bioscience's score of 0.00 indicating that iBio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iBio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
ZIVO Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

iBio has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

Summary

iBio beats ZIVO Bioscience on 10 of the 16 factors compared between the two stocks.

How does ZIVO Bioscience compare to Scilex?

Scilex (NASDAQ:SCLX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

ZIVO Bioscience has a net margin of 0.00% compared to Scilex's net margin of -1,185.78%.

Company Net Margins Return on Equity Return on Assets
Scilex-1,185.78% N/A -178.57%
ZIVO Bioscience N/A N/A -2,240.92%

ZIVO Bioscience has lower revenue, but higher earnings than Scilex. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scilex$30.25M1.82-$358.73M-$36.45N/A
ZIVO Bioscience$15.85K931.70-$7.78M-$2.59N/A

Scilex has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

69.7% of Scilex shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 4.1% of Scilex shares are held by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Scilex had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Scilex and 1 mentions for ZIVO Bioscience. Scilex's average media sentiment score of 1.70 beat ZIVO Bioscience's score of 0.00 indicating that Scilex is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scilex
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
ZIVO Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Scilex beats ZIVO Bioscience on 8 of the 13 factors compared between the two stocks.

Get ZIVO Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZIVO vs. The Competition

Export
MetricZIVO BioscienceBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$14.77M$327.75M$6.27B$12.28B
Dividend YieldN/AN/A2.80%5.35%
P/E Ratio-0.76N/A20.4725.38
Price / Sales931.70165.91540.5973.72
Price / CashN/A22.4443.2656.33
Price / Book-4.564.729.826.85
Net Income-$7.78M-$132.96M$3.55B$333.62M
7 Day Performance-1.60%-0.10%0.67%-0.07%
1 Month Performance65.62%10.80%-0.40%1.79%
1 Year Performance-79.50%57.57%37.38%32.91%

ZIVO Bioscience Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZIVO
ZIVO Bioscience
N/A$3.69
flat		N/A-79.5%$14.77M$15.85KN/A10
HYFT
MindWalk
3.0356 of 5 stars		$1.26
flat		$5.00
+296.8%		N/A$58.16M$28.08MN/A80
LIXT
Lixte Biotechnology
0.8562 of 5 stars		$5.04
+0.8%		N/A+238.0%$58.09MN/AN/A4
KALA
KALA BIO
2.3327 of 5 stars		$3.09
+1.0%		$1,018.75
+32,869.3%		-98.1%$56.88MN/AN/A30
IBIO
iBio
4.5577 of 5 stars		$1.56
+0.6%		$4.75
+204.5%		N/A$56.02M$400KN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ZIVO) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
"Golden Dawn": the code name that should be on every investor's radar
Trump's team has officially code-named America's new AI initiative 'Golden Dawn' - a government project involv...
InvestorPlace | Sponsoredtc pixel